

ASX RELEASE

ASX Code: ESE

29 June 2020

Notice Under Section 708A(5) of the Corporations Act 2001

This notice is given by eSense-Lab Limited (**ASX:ESE**) ("**eSense**" or the "**Company**") in relation to the issue of 62,500,000 CHESS Depositary Interests over ordinary shares (**Shares**) by the Company on 29 June 2020 pursuant to the Loan Notes (the terms of which were announced on 14 April 2020).

Further information relating to the issue of the Shares is detailed in the attached Appendix 2A.

The Corporations Act 2001 (Cth) (**Act**) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares detailed in the attached Appendix 2A will fall within the exemption in section 708A(5) of the Act.

Pursuant to section 708A(5)(e) of the Act the Company gives notice that:

- a. the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- b. the Company is providing this notice under paragraph (5)(e) of section 708A of the Act;
- c. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company;
- d. as at the date of this notice, the Company has complied with section 674 of the Act; and
- e. as at the date of this notice, there is no information:
 - i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - ii. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - A. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - B. the rights and liabilities attaching to the Shares.

The Company notes that it is in negotiations with various parties in relation to potential distribution agreements for products that are the subject of the recent joint ventures announced to ASX. Details on these arrangements will be announced to ASX if and when the Company is able to conclude negotiations and sign binding agreements.

This announcement has been authorised by the Board of Directors of eSense.

Ends

For further information, please contact:

Company Secretary

James Bahen

+61 8 6555 2950

info@esense-lab.com

Investor Enquiries

Gigi Penna

+61 404 147 568

info@esense-lab.com

About eSense-Lab | Registered office: Suite 6, 295 Rokeby Road, Subiaco Western Australia, Australia 6008

eSense-Lab Ltd (ASX:ESE) is a life sciences company creating virtual plant-based products for medicinal and recreational consumption. Headquartered in Israel, eSense-Lab combines genetics, mRNA expression, phytochemical characterisation and unique formulations to





generate comprehensive models of rare or high value plants. With multi-disciplinary research and development expertise, eSense has game-changing techniques and unique reverse-engineering capabilities, placing it at forefront of the growing international terpene market. eSense has created virtual cannabis, with all the characteristics of the real plant, without the psychoactive and heavily regulated cannabinoid compound, for mass consumer consumption.

To learn more, please visit www.esense-lab.com.

